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Exercise and Cancer Treatment - Research Article
Introduction
Cardiovascular disease ranks second as the leading cause of 
death among individuals who underwent cancer treatment.1 
Cardiotoxicity can be induced among cancer survivors by 
chemotherapeutic agents and by radiation.2,3 Cardiotoxicity 
appears as damage to the heart muscle, arrhythmias, cardiac 
ischemia, pericardial disease and heart failure.4 As a result 
of cardiotoxicity, cancer patients and survivors may experi-
ence a disruption of vagal regulation (ie autonomic dys-
function) and a decrease in cardiorespiratory fitness.5,6 
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Abstract
Cardiotoxicity as a result of cancer treatment contributes to autonomic dysfunction and decreased cardiorespiratory 
fitness among cancer survivors. These deleterious cardiovascular outcomes reduce the survival prognosis for cancer 
patients and contribute to poor quality of life among survivors. Exercise interventions have been shown as effective in 
mitigating treatment-related side effects. However, previously published interventions have not explored the potential 
for improvement in autonomic dysfunction (heart rate variability, HRV). This study examined cardiovascular adaptations 
in cancer survivors (n = 76) who participated in a 26-week intervention consisting of combined aerobic and resistance 
training (CART). The most noteworthy improvements occurred during the first 13 weeks of training and were maintained 
throughout the end of the 26-week period. HRrest improved from baseline (PRE) to the midpoint (MID) (P = .036) and 
from PRE to POST timepoints (P = .029). HRV and VO2max did not initially appear to change in response to CART. 
However, after stratification on time since treatment, participants who were 5 or more years from their last treatment 
experienced improvements (ie increase) in the HRV characteristic of HF power (P = .050) and also in VO2max (P =.043), 
when compared to those experiencing less than 5 years of time since their last treatment. These findings highlight a 
need for more attention to address the cardiorespiratory deficits experienced by those who have recently completed 
cancer treatment. In conclusion, the CART intervention is effective in improving cardiorespiratory fitness and autonomic 
dysfunction. The structure of the intervention is feasible for cancer survivors to continue with at home, using minimal 
resources, and without supervision. This at-home model may be even more acceptable to recent survivors that may be 
homebound immediately following treatment.
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Regular exercise participation, including combined aerobic 
and resistance exercise, may promote adaptations in vagal 
tone and cardiorespiratory fitness among cancer survivors.
Disruption of vagal tone, also known as autonomic dys-
function, can be measured as a detrimental change in heart 
rate variability (HRV) and/or an increase in resting heart 
rate (HRrest). Changes in HRV and HRrest may not be per-
ceived by an individual cancer survivor as an immediate 
concern, however, the long-term impact is deleterious and 
can contribute to increased mortality among cancer survi-
vors as well as an increase in daily fatigue.3,6,7 Autonomic 
dysfunction is associated with reduced parasympathetic 
efficacy and increased sympathetic overdrive, which can 
negatively affect heart health by increasing cardiovascular 
strain and increasing the risk for premature death.8 Analysis 
of HRV is the standard autonomic regulation assessment 
method and allows for the quantification of variances in the 
sinus rhythm.
HRV can be expressed using a frequency domain method 
as different spectrum powers to compare parasympathetic 
and sympathetic modulation.9 Specifically, low frequency 
(LF) power (ms2) indicates both sympathetic and parasym-
pathetic control and high frequency (HF) power is the 
“respiratory sinus arrhythmia” and indicates primarily para-
sympathetic control.10,11 Increases in HF power measure-
ments have been observed to correlate with resting 
bradycardia (low resting heart rate), improved physical fit-
ness, and a decreased risk for cardiovascular events.12,13 
Given that increased parasympathetic control signifies 
improved heart health, an improvement in HRV is indicated 
by an increase in HF power (parasympathetic control) or a 
decrease in the LF/HF power ratio.9,14 Measures of HRV 
and HRrest have been associated with physical fitness in 
healthy populations, but vagal control adaptations in 
response to exercise in cancer survivors are not well under-
stood.15 The expected exercise-related improvements in 
vagal tone may be salient in cancer survivors given the 
long-term effects of cardiotoxicity on morbidity and mor-
tality in this population.
In addition to vagal tone, disruption of cardiorespiratory 
fitness is often the most reported cardiovascular conse-
quence of cancer treatment because of fatigue and the 
reduced ability to partake in activities requiring higher met-
abolic demands.16 Further, cardiorespiratory fitness is a pre-
dictor of cancer-related mortality.16 Cardiorespiratory 
fitness (VO2max) can be measured directly or indirectly, and 
the latter can be carried out by assessment of maximal effort 
or estimated from submaximal values. Using submaximal 
exercise is a well-established practice for assessment of 
older individuals and individuals with a history of chronic 
conditions, such as cancer.17,18 Previously published studies 
support the efficacy of aerobic exercise prescription in 
improving cardiorespiratory fitness among cancer survivors 
post-treatment.19 However, less is known regarding the 
benefits of a combined aerobic and resistance training 
(CART) intervention among cancer survivors on cardiore-
spiratory fitness. HRV is understudied in general in cancer 
patients/survivors and, specifically, there is a paucity of 
research on the effect of CART on HRV in this population. 
Expanding the current understanding of cardiovascular 
adaptation among cancer survivors beyond HRrest and car-
diorespiratory fitness to include HRV will provide oncolo-
gists, physiatrists, and clinical exercise physiologists with a 
more comprehensive assessment of the long-term cardio-
vascular prognosis for their patients. Furthermore, explor-
ing the potential for changes in both vagal tone and 
cardiorespiratory fitness in response to a CART interven-
tion will align with the intent of the current American 
College of Sports Medicine (ACSM) recommendations for 
weekly bouts of both aerobic exercise and resistance 
training.
The psychosocial and physiological benefits of regular 
exercise among cancer survivors are well documented, 
including improvements in quality of life, body composi-
tion, cardiorespiratory fitness (ie VO2max), and insulin sensi-
tivity.19 Initially, the majority of exercise interventions 
among cancer survivors focused on aerobic exercise and its 
relationship with improved cardiorespiratory fitness and 
body composition.19 However, resistance training should be 
an integral component when designing exercise interven-
tions for cancer survivors to combat the muscle atrophy 
associated with most cancer treatments.20 Accordingly, the 
utilization of CART protocols have increased, with the 
majority of studies involving participants performing aero-
bic and resistance training on separate days or include aero-
bic exercise followed by a resistance training circuit of 
traditional strength exercises (ie leg press, chest press, 
seated row).21-23 These CART interventions among cancer 
survivors have demonstrated significant improvements in 
cardiorespiratory fitness,24,25 yet there are potential limita-
tions to the sustainability of a traditional gym-based CART 
approach. The gym-based protocols often include a high 
training volume (intensity and frequency) and participant 
time commitment, require specialized equipment, and are 
individualized which means that the important element of 
social support found in partnered or group-exercise is often 
missing. Furthermore, studies that have implemented more 
feasible training protocols such as body-weight resistance 
exercises (ie crunches, burpees), may not be suitable for 
cancer survivors with severe physical limitations.26
Overall, there is a need to determine the efficacy of fea-
sible CART protocols that are appropriate for cancer survi-
vors at various post-treatment stages and that can be 
implemented in group or community-based settings. The 
pilot study presented herein aims to address this need by 
examining cardiovascular adaptations, including vagal 
tone, heart rate variability and cardiorespiratory fitness, 
among cancer survivors following a 26-week CART 
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intervention administered in a group setting. First, we 
hypothesize that participants will experience significant 
improvements in vagal tone (ie HRV and HRrest) and cardio-
respiratory fitness (ie VO2max) at mid- and post-intervention 
timepoints. Second, we hypothesize that in light of the car-
diotoxic effects of treatment, those individuals with a 
shorter time since treatment cessation will experience less 
improvement in vagal tone and cardiorespiratory fitness 
compared to those who have reached the 5 or more years 
milestone for treatment cessation.
Methods
Overview of the Intervention
The Improving Physical Activity After Cancer Treatment 
(IMPAACT) Study used an exercise prescription of com-
bined aerobic and resistance training (CART) with the addi-
tion of core strengthening and flexibility. Primary outcomes 
were measured at 3 timepoints over a 26-week intervention 
period and included baseline-to-midpoint and midpoint-to-
post-intervention changes in vagal tone and cardiorespira-
tory fitness by measuring HRV (Low Frequency Power, 
High Frequency Power, LF/HF ratio), HRrest, and VO2max in 
cancer survivors. The study protocol was approved by the 
Institutional Review Board at Loyola Marymount University 
and the State of California Committee for the Protection of 
Human Subjects.
Participants
Cancer survivors were recruited using the Los Angeles 
Cancer Surveillance Program as well as convenience sam-
pling and physician referral. Volunteers provided written 
informed consent to participate in the study and were asked 
to complete a questionnaire that used a closed-question 
structure to collect information pertaining to demographic 
characteristics, medical history, and health behaviors. 
Volunteers were excluded if at least 1 of the following con-
ditions was present: (1) recurrent cancer or new primary 
diagnosis, (2) currently undergoing chemotherapy, (3) had 
suffered myocardial infarction or stroke within 1 year of 
enrollment date, (4) had history of fainting while exercis-
ing, (5) had history of chest pain or shortness of breath as a 
result of physical activity, and (6) had lymphedema or 
inflammation of lower extremities or pelvis. Prior to the 
intervention, participants were asked to inform their physi-
cians of their planned participation and to review the exer-
cise and assessment protocols.
Intervention Design
The IMPAACT Study incorporated a CART program con-
sisting of one-hour sessions, offered 3 times per week, for 
26 weeks at an academic facility. Each session included 
20 minutes of cardiorespiratory training, 30 minutes of cir-
cuit-style resistance training and balance exercises, and 
10 minutes of static and dynamic stretching. A Certified 
Clinical Exercise Physiologist® and other study personnel 
certified by the American College of Sports Medicine 
(ACSM) designed the program according to the ACSM 
Guidelines for Exercise for Cancer Survivors.27 Participants 
wore heart rate monitors during each session and monitored 
their exertion based on prescribed individual intensity of 
the training heart rate zone. In combination with medical 
history and current level of physical activity and aerobic 
fitness, each participant’s target heart rate zone (% of heart 
rate reserve) was derived from the Karvonen formula, using 
age-predicted HRmax.
Participants engaged in cardiorespiratory training by 
either walking/jogging outdoors or using a stationary bike 
or elliptical machine indoors to reach their personalized 
target heart rate zone. The designated route for walking/
jogging was mapped out for participants on an academic 
campus in close proximity to the academic circuit/strength/
flexibility training facility and was without incline, obsta-
cles, or trip hazards. The route was designed as a one-third 
of a mile loop with the beginning of the loop at the entry 
point to the academic training facility. Initial heart rate 
zone prescription for all participants was 35% to 50% 
depending on clinical/medical history and functional and 
physical ability as determined by baseline testing. Over 
the course of the study, heart rate zones were reviewed 
once weekly and adjusted every 2 weeks with an average 
change of 0% to 5%.
The circuit-training portion followed the cardiorespira-
tory training and included 10 stations of alternating upper 
and lower body resistance-based exercise, balance activi-
ties, and vibration plates. During the first 2 weeks of train-
ing, participants completed 2 sets of the 10 exercise stations 
for a total of 2 minutes per station with 60-second transi-
tion/rest periods between stations. Longer time at each sta-
tion allowed for participants to familiarize themselves with 
exercise technique and allowed the trainers to determined 
most appropriate resistance/modality at each station. The 
training progressed toward 3 sets of the 10 exercise stations 
with each station performed for 45 seconds with a 20-sec-
ond transition/rest period between stations. Variations in 
exercise intensity were provided at each resistance exercise 
station including different band strengths or dumbbell 
weights. Exercise intensity was monitored via heart rate and 
participants were encouraged to maintain their target heart 
rate zones throughout the cardiovascular and resistance 
training portions. Further, principles of overload and pro-
gression were considered and intensity levels (repetitions, 
sets, weight, and color of band or tubing) were recorded on 
participant’s exercise cards. Progression of intensity was no 
more than 5% and 10% for upper body and lower body 
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exercises per week, respectively. Sample exercises included 
in the exercise circuit were resistance band rows, squats, 
forward/backward and lateral lunges and stepping, abdomi-
nal exercise variations, push-ups, or overhead press. 
Participants used resistance bands and tubing or light hand 
and ankle weights to increase the load. Balance exercises 
included a variety of movements that targeted visual, ves-
tibular and somatosensory systems, postural control and 
strategies, as well as center of gravity control and gait pat-
tern variations exercises. Two stations included vibration 
plates on which the participants progressed from standing 
with knees slightly bent to partial and full squats and calf 
raises based on tolerance. All exercises were designed to 
potentially mediate deficits in body composition, aerobic 
fitness, muscular strength, bone density and neuropathy, 
conditions known to be present among cancer survivors.28
All participants were offered customized modification at 
each station depending on their physical ability. The circuit 
session concluded with a 10-minute period of approxi-
mately 5 core exercises performed for 2 sets for 30 seconds 
each (ie chair leg raises, curl-ups, seated side bends) fol-
lowed by 5 minutes of static stretching of major muscle 
groups with participants choosing to stretch while seated or 
while standing with support from a chair.
Fidelity to the Intervention
Attendance was recorded during each exercise session to 
measure program adherence. Participants self-monitored 
prescribed heart rate zones by wearing heart rate monitors 
during the entire exercise session. Throughout the interven-
tion the prescribed zones began at 35-50% of participants’ 
heart rate reserve, with the individual range increasing based 
on participant’s ability to maintain the intensity, their per-
ceived exertion, and regular attendance. Participants strove 
to exercise continuously during the duration of each station 
while maintaining their intensity within the prescribed heart 
rate zones. The ratio of trainers-to-participants at each ses-
sion was minimally 1:4. Trainers were a consistent source of 
encouragement and could regularly remind participants to 
check their heart rate monitors to maintain their exertion lev-
els and to breathe rhythmically without holding the breath. 
Trainers also helped participants prepare to transition to the 
next station during circuit training. Participants were able to 
walk alone or with 2 or more walking buddies during the 
aerobic exercise portion. Participants were paired with 1 or 
2 other people at each circuit station and the static and 
dynamic stretches were performed as a group.
For each session, 1 trainer held the responsibility of cir-
culating among participants and recording heart rates and 
exertion levels at the beginning of the aerobic session and at 
the beginning of each lap that participants made on the des-
ignated walking/jogging route. These data were collected 
again at the end of the aerobic session and prior to the start 
of the circuit training, with participants being reminded to 
continue to walk around and keep their legs moving while 
they had a water break. At the end of the circuit training ses-
sion and prior to the core/flexibility session another round 
of data collection occurred. The last point of data collection 
took place at the end of the core/flexibility session.
Outcome Measures
Vagal tone and HRV. Prior to testing, participants were 
instructed to abstain from caffeine-containing foods and 
drinks and other stimuli known to affect heart rate as well as 
vigorous exercise at least 24 hours before assessment and 
were asked to refrain from large meals 3 hours prior to test-
ing. No participants were prescribed hormonal treatments 
over the course of the study and 6 participants were pre-
scribed beta blockers. Participants completed exercise test-
ing while on their prescribed medications and researchers 
ensured participants were on the same dose of medication at 
all testing timepoints. Further, participants completed test-
ing at the same time of day for pre, mid, and post testing 
timepoints. Upon arriving at the laboratory, participants 
were familiarized with testing procedures. To assess resting 
heart rate, (HRrest), participants rested supine in a laboratory 
room with decreased sensory stimulation for a 10-minute 
period. Breathing was paced at 12 cycles of inhalations and 
exhalations per minute using a metronome to minimize the 
effect of respiratory influence. The 10-minute recording 
started once the participants comfortably synced their 
breath with metronome and a 7-minute period was eventu-
ally evaluated; it was selected by excluding recordings with 
large R-R interval outliers and by adhering to R-R interval 
equidistance.29 HRrest was determined as the lowest number 
of beats per minute (bpm) during the 10-minute period and 
was recorded from a Polar RS800CX (Polar Electro, Lake 
Success, NY) training computer. R-R intervals were mea-
sured simultaneously on the same device and were then 
transferred to the Kubios software package (version 2.2) for 
analysis of HRV.30 HRV data was pre-processed within 
Kubios to automatically remove artifacts and ectopic beats 
using a medium (0.25 seconds) threshold value for each par-
ticipant. Specific outcome measures of HRV include LF 
power (ms2), HF power (ms2), and LF/HF ratio (ms2).
Cardiorespiratory fitness. Cardiorespiratory fitness (VO2max) 
was estimated from a submaximal YMCA protocol on a 
cycle ergometer.31 The YMCA test has demonstrated strong 
criterion validity against a maximal treadmill test in adults 
(r = 0.77).31 A validated submaximal exercise test was cho-
sen for this study instead of a maximal exercise test because 
of participants’ history of cancer and cancer treatment and 
self-reporting of reduced exercise capacity and physical 
functioning during recruitment and screening.32 The YMCA 
test is an incremental exercise test during which the heart 
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rate response is logged in response to progressive resistance 
load at a cadence of 50 revolutions per minute (rpm). The 
test concludes successfully when the participant reaches 2 
steady-state periods marked by heart rate readings of no 
more than 6 beats apart per minute within an intended range 
of 110 bpm and 85% of the age-predicted maximal heart 
rate. Participants maintained a cadence of 50 rpm during a 
cool-down period.
Statistical Analysis
Descriptive statistics are given as mean ± standard devia-
tion for participant characteristics or mean with 95% confi-
dence intervals for outcome measures, and number with 
percentage for qualitative variables. Normality was verified 
for all variables using histograms and box-plots. Time since 
treatment was collected as a continuous variable (years) and 
coded as a categorical variable (<5 years and ≥5 or more 
years).33,34 Given the emphasis on the cardiotoxicity associ-
ated with chemotherapy and radiation, the treatment vari-
able was collapsed into a two-category variable of 
chemotherapy and/or radiation exposure versus no chemo-
therapy/radiation exposure. Mann-Whitney U test proce-
dure was used to examine whether there was any difference 
in the change of each outcome at different timepoints by 
race and treatment type. Separate repeated measures analy-
sis of variance (ANOVA) tests were used to determine 
changes in outcome measures across the 3 timepoints (PRE, 
MID, and POST). Sample size for each analysis may vary 
as a result of incomplete assessment data. Post hoc tests 
were done on least-squares means using a Tukey adjust-
ment for multiple comparisons. Log transformation was 
used when the assumptions were not met. For outcome 
measures that improved significantly across time points, a 
Pearson Chi-square test was performed to determine the 
proportion of participants that improved measures of car-
diovascular function from PRE to MID and from PRE to 
POST timepoints for groups attending ≤50% of sessions 
and those attending >50% of sessions throughout the inter-
vention. All statistical tests were performed at an α = 0.05 
significance level. Statistical analyses were performed 
using SPSS (Version 26; IBM Corporation 1989, 2019) and 
SAS (Version 9.3; SAS Institute Inc.).
Results
Demographics
Participant demographics for the pooled cohort (n = 76) at 
baseline are shown in Table 1. Demographics for the 2 indi-
vidual cohorts have been published previously.34 Participants 
had a mean age of 62.9 ± 10.1 years and reported their pri-
mary cancer site as follows: breast (39.5%), endometrial 
(15.8%), gynecological (10.5%), colorectal (9.2%), 
Hodgkin’s lymphoma and uterine (5.3% each), melanoma 
and thyroid (3.9% each), prostate (2.9%), and other (12.9%). 
At baseline, our sample was characterized as overweight 
with an average BMI of 28.5 ± 6.4 kg/m2.
Intervention Participant Adherence
Average exercise session attendance was 59.0 ± 18.1%, 
with the lowest attendance rate at 11.3% and highest rate at 
96.3%. Reasons for lack of attendance included musculo-
skeletal issues, injuries/accidents unrelated to exercise 
intervention, vacations, return to treatment, or death unre-
lated to the exercise intervention. Number of sessions 
attended (<50% vs ≥50%) in the intervention was similar 
between White and non-White participants (P = .099).
Intervention-Associated Changes in Outcome 
Measures
Participant changes in outcome measures from base-
line/0 weeks (PRE), midpoint at 13 weeks (MID), and post-
intervention at 26 weeks (POST) are summarized in Table 2.
Vagal tone and HRV. HRrest improved from PRE to MID 
(P = .036) and from PRE to POST timepoints (P = .029) 
(Table 2). These improvements were not modified by treat-
ment type (P = .965) or race (P = .488). When HRrest was 
Table 1. Participant Characteristics at Baseline for the 
IMPAACT Study (n = 76).
Item Category n† % of sample
Gender Men 7 9.2
Women 69 90.8





<5 years 36 52.2
≥5 years 33 47.8
Treatment type Surgery/other 25 32.9
Chemotherapy/radiation 51 67.1
Smoking status* Never smoked >100 




Education* Some college or less 18 24.0
College graduate 57 76.0
Sleep/night* 4 or less hours 1 1.3
5-6 hours 43 57.3




Needs improvement 45 60.0
*P < .05 between category groups.
†Sample size is varied due to incomplete survey data.
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examined across categories of participation frequency 
(<50% sessions attended vs ≥50% sessions attended), 
there was no modification of the observed change in HRrest 
from PRE to MID (P =.703) or from PRE to POST time-
points (P = 1.000) (Figure 1). HRrest was also examined 
across categories of time since treatment (<5 years TST, 
≥5 years TST) and data are presented in Figure 2. A larger 
percentage of participants in the ≥5-year TST group expe-
rienced an improvement (ie decrease) in HRrest from PRE to 
MID timepoints, as compared to the <5 years TST group, 
however, this difference was not statistically significant 
(P = .778).
With regard to HRV outcomes (Table 2), there was no 
observed change in LF power, HF power, or the LF/HF 
power ratio from PRE to MID or from PRE to POST 
(P > .050). Treatment type did not modify the observa-
tions for HF power (P = .710) or LF power (P = .678). 
When race was considered, a suggested change was noted 
for HF power (P > .075) between PRE to MID, but not for 
LF power (P > .394). When time since treatment was 
considered, a change was observed for HF power 
(P = .050), reflecting that a greater number of participants 
in the ≥5 year TST group experienced improvements (ie 
increase) in HF power between PRE and MID timepoints 
compared to cancer survivors in the <5 year TST group 
(Figure 2). There was no observed difference in the num-
ber of participants demonstrating improvements (ie 
decrease) in LF power between TST groups (P = .329) 
(Figure 2).
Cardiorespiratory fitness. Changes in VO2max were not appar-
ent from PRE to MID or from PRE to POST timepoints 
(P >.05) (Table 2). VO2max across timepoints was not modi-
fied by race (P = .657) or treatment type (P = .732). In a Chi 
Square analysis of time since treatment, more participants 
in the ≥5-year TST group experienced improvements in 
VO2max (P = .043) compared to participants in the <5-year 
TST group (Figure 2).







n(0 weeks) (13 weeks) (26 weeks)
HRrest (bpm)
†* 71.1 (67.1, 75.3) 76 65.1 (62.1, 67.6) 63 64.8 (62.3, 67.5) 53
VO2max (mL/kg
/min)† 22.2 (20.0, 24.5) 69 21.5 (19.2, 24.0) 57 21.3 (18.8, 24.0) 47
Low frequency (LF) power (ms2)† 269.4 (192.8, 376.5) 62 228.5 (162.6, 321.1) 60 203.1 (137.7, 299.5) 46
High frequency (HF) power (ms2)† 187.6 (125.4, 280.7) 62 196.1 (130.2, 295.4) 60 174.4 (109.2, 278.5) 46
LF/HF Power (ms2)† 1.4 (1.1, 1.8) 62 1.1 (0.9, 1.4) 60 1.1 (0.8, 1.5) 46
Data reported as mean (95% Confidence Interval): bpm = beats per minute. Sample size may vary due to the inability of a small number of participants 
to complete the assessment battery.
†Based on log transformed variable.






Reduction in HRrest from 
PRE to MID
Reduction in HRrest from 
MID to POST
Reduction in HRrest from 
PRE to POST



























Figure 1. Percent of participants experiencing a reduction in resting heart rate (HRrest) from baseline (PRE) to 13 weeks (MID), from 
MID to 26 weeks (POST), and from PRE to POST for participants attending ≤50% of sessions compared to participants attending 
>50% of sessions.
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Discussion
This pilot study examined cardiovascular adaptations (ie 
HRV and cardiorespiratory fitness) following a 26-week 
combined aerobic and resistance training (CART) interven-
tion, implemented in a group setting. Improvements in out-
comes were most prominent between the PRE to MID 
timepoints, suggesting that the initiation of participation in 
CART was most beneficial during the first 13 weeks of the 
intervention. Changes in outcomes did not reach statistical 
significance from MID to POST, which indicates that partici-
pants may have experienced a plateau effect in their training 
adaptations. However, improvement in HRrest was progressed 
during MID to POST timepoints and the improvements in 
several outcomes from the PRE to MID training period were 
sustained during the MID to POST training period.
Improvements in Vagal Tone
HRrest improved from PRE to MID timepoints, demonstrat-
ing improved cardiovascular function following our CART 
intervention. Interestingly, improvements in HRrest did not 
vary by treatment type, race, or time since treatment, sug-
gesting that our CART program may be sensitive to elicit 
improvements in cancer survivors independent of their time 
since treatment status. Specifically, the decrease in HRrest 
observed may be attributed to an improvement in parasym-
pathetic modulation and/or improvements in cardiorespira-
tory fitness in our sample of cancer survivors.11 However, it 
is difficult to attribute potential mechanisms to explain or 
our findings given that there were no changes initially 
observed for cardiorespiratory fitness or HF power (para-
sympathetic control) or LF power (parasympathetic/sympa-
thetic control) across timepoints and no variation with 
treatment type, time since treatment (cardiorespiratory fit-
ness only), or race (LF power only). Nonetheless, the varia-
tion suggested with race for HF power should be explored 
further to separate potential biological characteristics of 
cardiovascular adaptation and race from external character-
istics (eg psychosocial stressors) that may influence para-
sympathetic control and time since treatment.
In the current study, participants in the ≥5-year TST 
group experienced the greatest improvement in HF power, 
likely because they are further from the cardiotoxic effects 
of treatment. Similar to our findings, Caro-Morán et al15 
examined vagal tone in breast cancer survivors who were 
less than 1 year from treatment cessation and demonstrated 
significantly lower HF power among cancer survivors com-
pared to age-matched controls. These differences in HRV 
have been frequently attributed to cancer therapies that 
include the anthracycline- and trastuzumab- containing reg-
imens, or to new adjuvant cytotoxic (taxane-containing) 
agents and hormonal regimens (aromatase inhibitors) in 
which several of the participants in the present study com-
pleted.35 However, Cramer et al36 found that patients with 
colorectal cancer had compromised vagal tone regardless of 
whether they underwent chemotherapy or not, suggesting 
that a different mechanism might negatively affect auto-
nomic function. For example, vagal tone disparities may 
resolve over time with a washing out of treatment effects 
which may explain why participants longer from treatment 
experienced greater improvements in parasympathetic con-
trol. Findings from this current pilot study are consistent 
with the aforementioned studies in that: (a) the effect of 
treatment appears to lag well into the survivorship period 
with an eventual washout of cardiotoxicity after 5 or more 
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Figure 2. Percent of participants who demonstrated improvement in outcome measures from baseline (PRE) to 13 weeks (MID) for 
participants within 5 years of treatment (TST < 5 years) compared to participants who received their last treatment 5 or more years 
prior to study onset (TST ≥ 5 years).
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tone and perhaps there is another determinant of the cancer 
experience that is influencing HRV. Another potential 
mechanism that may explain the lack of effect of exercise 
on vagal tone is the intra-individual variability in daily HRV 
measures. For example, participants completing cancer 
treatment more recently may experience greater variability 
and therefore using an isolated daily HRV measurement as 
in the present study may have confounded the results. 
Therefore, future research investigating the effects of exer-
cise training on HRV among cancer survivors may com-
plete more robust HRV analyses including weekly 
coefficients of variation as performed in athlete monitoring 
investigations37 to account for the high variability in recent 
cancer survivors.
Improvements in Cardiorespiratory Fitness
Our study demonstrated no changes for VO2max across time-
points and no variation by race or treatment type. However, 
similar to certain vagal tone outcomes, we observed a better 
outcome for those survivors that are further from the cardio-
toxic effects of treatment. In contrast to our findings, Dieli-
Conwright and colleagues demonstrated an increase in 
estimated VO2max in breast cancer survivors following a 
6-month aerobic and resistance training intervention with a 
prescribed exercise intensity of 65-85% heart rate maxi-
mum.22 The inability to detect a change in cardiorespiratory 
fitness in the current study may be attributed to our sample 
size and/or to our use of a submaximal protocol for assess-
ing VO2max. For example, some participants were unable to 
match their efforts during the MID or POST YMCA sub-
maximal bicycle tests due to physical limitations at the time 
of assessment. Further, prescribed intensity for aerobic 
exercise was individualized based on the current health sta-
tus and physical limitations of the participant, and the inten-
sity may not have been sufficient to elicit significant 
improvements in VO2max comparable to previous studies 
that utilized a higher exercise intensity.22
Limitations and Strengths
This pilot study’s sample size is small, however, it remains 
comparable in size to other studies examining exercise 
interventions in cancer survivors.38,39 The study is designed 
as a prospective analysis of a single intervention group and 
is limited by the absence of a control group. The study is 
strengthened by a relatively long intervention period of 
26 weeks, which allows for longitudinal assessment of indi-
vidual progress at multiple, meaningful timepoints. Our 
sample was heterogeneous in terms of types of cancer site, 
however, researchers have previously reported that cancer 
type did not affect exercise-mediated cardiovascular out-
comes.40 Further, this study examined a more feasible 
CART program implemented in a group-based setting 
compared to traditional gym-based CART programs requir-
ing specialized equipment and a high training volume.22
The midpoint assessments took place at the conclusion 
of the first 13-week training period and were followed by a 
month-long break in supervised training due to the aca-
demic training setting and respect for observance of reli-
gious/ethnic holidays. Participants were provided with 
at-home instructions for the CART intervention in order to 
maximize intervention fidelity. The intervention at the aca-
demic facility was designed to be adaptable to a home set-
ting and without reliance on specialized equipment or 
spaces. As such, the at-home adaptations were identical to 
those in the academic facility and participants were already 
trained in the intervention protocol by participating for the 
first 13 weeks. Participants were given resistance bands and 
hand weights to use at home, along with a printed interven-
tion protocol guidebook with pages to record daily progress 
and HR monitor readings, and their own Polar watches/
chest straps. The month away from the supervised program 
may have contributed to a lack of improvement in outcomes 
during the MID to POST timepoints, but it did not have a 
deleterious effect on the gains from the PRE to MID time-
points. Participant improvements noted at MID were main-
tained throughout the second 13 weeks of the training 
program (MID through POST).
Further, leg fatigue or arthritic related complaints were 
the most common reasons reported by the participants who 
could not successfully finish YMCA submaximal test, 
which resulted in unequal sample sizes at the assessment 
timepoints. Our assessment experience raises a question 
regarding the best way of determining cardiorespiratory fit-
ness in a population of cancer survivors. It is challenging to 
accommodate the varied ability levels coupled with a wide 
age range in a highly heterogeneous group. Whereas the 
walking mode can serve participants with higher mobility 
or those unable to stay seated for longer periods of time (eg 
patients treated for colorectal cancer), cycling provides a 
safer mode for cancer survivors suffering from treatment-
related balance issues.41
Conclusion and Practical Implications
This pilot study examined the effects of a CART intervention 
on both cardiorespiratory fitness and vagal tone in cancer sur-
vivors. It is worth noting that the CART intervention was 
acceptable to older cancer survivors that could be character-
ized as overweight and that self-reported a need to improve 
their physical activity levels. Attendance among participants 
varied, however, frequency of participation did not signifi-
cantly change the intervention efficacy. This may be due to 
the ease at which participants could self-monitor fidelity to 
the intervention using a heart rate monitor and basic Likert 
scale assessment of exertion, regardless of the type of exer-
cise they were engaged in. In addition to the observed 
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improvements in resting heart rate for cancer survivors in 
response to CART, this study also demonstrates potential 
synchronicity between improvements in cardiorespiratory 
fitness and vagal tone (HF power/parasympathetic tone).
This study identifies a potential health disparity in the 
gains in both cardiorespiratory fitness and vagal tone as a 
result of proximity to treatment. Based on our findings, 
future studies should focus on exercise prescriptions that 
might be tailored to cancer survivors who have recently 
completed treatment in order to reduce vagal tone dispari-
ties in a safe and efficacious manner. During recovery and 
after cessation of physical activity, sympathetic withdrawal 
coupled with increased vagal input helps the body return to 
a resting state.42 HRV-guided training can help to individu-
alize exercise prescriptions not only for athletes but also for 
clinical populations. Enhanced levels of vagal input before 
an exercise bout as well as sufficient recovery state, that is, 
fully recovered vagal tone, both lead to better training 
response.43 Whereas the current exercise guidelines for can-
cer survivors are comprehensive, the protocol does not 
include the use of HRV as part of individualized exercise 
prescription. As the scientific community continues to 
explore the most effective forms of physical activity inter-
ventions, HRV lends itself to aid this process.38
The potential use of an at-home program as a “mainte-
nance therapy” after an initial supervised intervention 
increases the feasibility and scalability of CART to improve 
cardiovascular adaptations among cancer survivors. At-home 
interventions may also be implemented on virtual platforms 
to encourage partnered or group exercise while mitigating 
transportation barriers and restrictions on social distancing if 
a cancer survivor is experienced immune compromise as a 
treatment-related side effect.
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